Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB.

Nature. 2018 Feb 8;554(7691):189-194. doi: 10.1038/nature25475. Epub 2018 Jan 31.

PMID:
29420467
2.

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Demanse D, Blumenstein L, Coughlin C, Quadt C, Baselga J.

J Clin Oncol. 2018 Feb 5:JCO2017727107. doi: 10.1200/JCO.2017.72.7107. [Epub ahead of print]

PMID:
29401002
3.

Effects of White Wine Consumption on Weight in Rats: Do Polyphenols Matter?

Milat AM, Mudnić I, Grković I, Ključević N, Grga M, Jerčić I, Jurić D, Ivanković D, Benzon B, Boban M.

Oxid Med Cell Longev. 2017;2017:8315803. doi: 10.1155/2017/8315803. Epub 2017 Oct 31.

4.

First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors.

Bédard PL, Davies MA, Kopetz S, Juric D, Shapiro GI, Luke JJ, Spreafico A, Wu B, Castell C, Gomez C, Cartot-Cotton S, Mazuir F, Dubar M, Micallef S, Demers B, Flaherty KT.

Cancer. 2018 Jan 15;124(2):315-324. doi: 10.1002/cncr.31044. Epub 2017 Oct 4.

PMID:
28976556
5.

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.

Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G Jr, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ.

BMC Cancer. 2017 Sep 12;17(1):646. doi: 10.1186/s12885-017-3641-6.

6.

A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies.

Juric D, de Bono JS, LoRusso PM, Nemunaitis J, Heath EI, Kwak EL, Macarulla Mercadé T, Geuna E, Jose de Miguel-Luken M, Patel C, Kuida K, Sankoh S, Westin EH, Zohren F, Shou Y, Tabernero J.

Clin Cancer Res. 2017 Sep 1;23(17):5015-5023. doi: 10.1158/1078-0432.CCR-16-2888. Epub 2017 May 10.

PMID:
28490463
7.

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.

Juric D, Krop I, Ramanathan RK, Wilson TR, Ware JA, Sanabria Bohorquez SM, Savage HM, Sampath D, Salphati L, Lin RS, Jin H, Parmar H, Hsu JY, Von Hoff DD, Baselga J.

Cancer Discov. 2017 Jul;7(7):704-715. doi: 10.1158/2159-8290.CD-16-1080. Epub 2017 Mar 22.

PMID:
28331003
8.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT.

J Clin Oncol. 2017 Jul 1;35(19):2141-2148. doi: 10.1200/JCO.2016.70.8297. Epub 2017 Mar 14.

PMID:
28291390
9.

Pseudopolyrotaxane Formation in the Synthesis of Cyclodextrin Polymers: Effects on Drug Delivery, Mechanics, and Cell Compatibility.

Thatiparti TR, Juric D, von Recum HA.

Bioconjug Chem. 2017 Apr 19;28(4):1048-1058. doi: 10.1021/acs.bioconjchem.6b00721. Epub 2017 Feb 8.

PMID:
28117991
10.

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.

Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V, Kambadakone A, Mussolin B, Reyes S, Henderson L, Sun JE, Van Seventer EE, Gurski JM Jr, Baltschukat S, Schacher-Engstler B, Barys L, Stamm C, Furet P, Ryan DP, Stone JR, Iafrate AJ, Getz G, Porta DG, Tiedt R, Bardelli A, Juric D, Corcoran RB, Bardeesy N, Zhu AX.

Cancer Discov. 2017 Mar;7(3):252-263. doi: 10.1158/2159-8290.CD-16-1000. Epub 2016 Dec 29.

11.

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.

Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, Primack B, Cao S, Bernhardy AJ, Coulson R, Lazaro JB, Kochupurakkal B, Sun H, Unitt C, Moreau LA, Sarosiek KA, Scaltriti M, Juric D, Baselga J, Richardson AL, Rodig SJ, D'Andrea AD, Balmaña J, Johnson N, Geyer M, Serra V, Lim E, Shapiro GI.

Cell Rep. 2016 Nov 22;17(9):2367-2381. doi: 10.1016/j.celrep.2016.10.077.

12.

Selective cytotoxicity of microcystins LR, LW and LF in rat astrocytes.

Bulc Rozman K, Jurič DM, Šuput D.

Toxicol Lett. 2017 Jan 4;265:1-8. doi: 10.1016/j.toxlet.2016.11.008. Epub 2016 Nov 15.

PMID:
27864109
13.

Histamine and astrocyte function.

Jurič DM, Kržan M, Lipnik-Stangelj M.

Pharmacol Res. 2016 Sep;111:774-783. doi: 10.1016/j.phrs.2016.07.035. Epub 2016 Jul 27. Review.

PMID:
27475882
14.

Hysteretic Faraday waves.

Périnet N, Falcón C, Chergui J, Juric D, Shin S.

Phys Rev E. 2016 Jun;93(6):063114. doi: 10.1103/PhysRevE.93.063114. Epub 2016 Jun 24.

15.

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.

Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, Juric D, Solit D, Berger MF, Won HH, Li Y, Cantley LC, Winer E, Arteaga CL.

Clin Cancer Res. 2017 Jan 1;23(1):26-34. doi: 10.1158/1078-0432.CCR-16-0134. Epub 2016 Apr 28.

16.

Hyperbaric oxygen preserves neurotrophic activity of carbon monoxide-exposed astrocytes.

Jurič DM, Šuput D, Brvar M.

Toxicol Lett. 2016 Jun 24;253:1-6. doi: 10.1016/j.toxlet.2016.04.019. Epub 2016 Apr 22.

PMID:
27113706
17.

Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance.

Wehrenberg-Klee E, Turker NS, Heidari P, Larimer B, Juric D, Baselga J, Scaltriti M, Mahmood U.

J Nucl Med. 2016 Sep;57(9):1413-9. doi: 10.2967/jnumed.115.169417. Epub 2016 Apr 14.

18.

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.

Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR Jr, Tabernero J, Roda D, Calles A, Jimeno A, Wang X, Bohórquez SS, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Baselga J.

Clin Cancer Res. 2015 Jun 1;21(11):2462-70. doi: 10.1158/1078-0432.CCR-14-2412.

19.

AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.

Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixidó C, Huang A, Ghossein RA, Rosen N, Bivona TG, Scaltriti M, Baselga J.

Cancer Cell. 2015 Apr 13;27(4):533-46. doi: 10.1016/j.ccell.2015.03.010.

20.

The effectiveness of oxygen therapy in carbon monoxide poisoning is pressure- and time-dependent: a study on cultured astrocytes.

Jurič DM, Finderle Ž, Šuput D, Brvar M.

Toxicol Lett. 2015 Feb 17;233(1):16-23. doi: 10.1016/j.toxlet.2015.01.004. Epub 2015 Jan 3.

PMID:
25562542
21.

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.

Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, Ebbesen SH, Ainscough BJ, Ramu A, Iyer G, Shah RH, Huynh T, Mino-Kenudson M, Sgroi D, Isakoff S, Thabet A, Elamine L, Solit DB, Lowe SW, Quadt C, Peters M, Derti A, Schegel R, Huang A, Mardis ER, Berger MF, Baselga J, Scaltriti M.

Nature. 2015 Feb 12;518(7538):240-4. doi: 10.1038/nature13948. Epub 2014 Nov 17.

22.

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.

Vora SR, Juric D, Kim N, Mino-Kenudson M, Huynh T, Costa C, Lockerman EL, Pollack SF, Liu M, Li X, Lehar J, Wiesmann M, Wartmann M, Chen Y, Cao ZA, Pinzon-Ortiz M, Kim S, Schlegel R, Huang A, Engelman JA.

Cancer Cell. 2014 Jul 14;26(1):136-49. doi: 10.1016/j.ccr.2014.05.020. Epub 2014 Jul 4.

23.

Metrifonate, like acetylcholine, up-regulates neurotrophic activity of cultured rat astrocytes.

Mele T, Jurič DM.

Pharmacol Rep. 2014 Aug;66(4):618-23. doi: 10.1016/j.pharep.2014.02.025. Epub 2014 Apr 26.

PMID:
24948063
24.

Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.

Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B, Ellis H, Morse N, Viola-Villegas NT, Bosch A, Juric D, Hazra S, Singh S, Kim P, Bergamaschi A, Maheswaran S, Ng T, Penault-Llorca F, Lewis JS, Carey LA, Perou CM, Baselga J, Scaltriti M.

Sci Signal. 2014 Mar 25;7(318):ra29. doi: 10.1126/scisignal.2005125.

25.

Is herbal tea consumption a factor in endemic nephropathy?

Ivković V, Karanović S, Fištrek Prlić M, Mišić M, Kos J, Jurić D, Vuković Lela I, Vitale K, Cvitković A, Laganović M, Fodor L, Edwards K, Grollman AP, Jelaković B.

Eur J Epidemiol. 2014 Mar;29(3):221-4. doi: 10.1007/s10654-014-9886-3. Epub 2014 Mar 13. No abstract available.

PMID:
24623403
26.

Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies.

De Buck SS, Jakab A, Boehm M, Bootle D, Juric D, Quadt C, Goggin TK.

Br J Clin Pharmacol. 2014 Sep;78(3):543-55. doi: 10.1111/bcp.12378.

27.

National program of colorectal carcinoma early detection in Brod-Posavina County (east Croatia).

Jurisić I, Paradzik MT, Jurić D, Kolovrat A, Cvitković A.

Coll Antropol. 2013 Dec;37(4):1223-7.

PMID:
24611338
28.

Identification and pharmacological characterization of the histamine H3 receptor in cultured rat astrocytes.

Mele T, Jurič DM.

Eur J Pharmacol. 2013 Oct 24. pii: S0014-2999(13)00785-1. doi: 10.1016/j.ejphar.2013.10.028. [Epub ahead of print]

PMID:
24513516
29.
30.

Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates.

Ullal AV, Peterson V, Agasti SS, Tuang S, Juric D, Castro CM, Weissleder R.

Sci Transl Med. 2014 Jan 15;6(219):219ra9. doi: 10.1126/scitranslmed.3007361.

31.

PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.

Ebi H, Costa C, Faber AC, Nishtala M, Kotani H, Juric D, Della Pelle P, Song Y, Yano S, Mino-Kenudson M, Benes CH, Engelman JA.

Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21124-9. doi: 10.1073/pnas.1314124110. Epub 2013 Dec 10.

32.

Upper urothelium carcinomas in Croatian endemic area.

Cvitković A, Ivić-Hofman I, Jurić D.

Wien Klin Wochenschr. 2013 Sep;125(17-18):529-36. doi: 10.1007/s00508-013-0412-5. Epub 2013 Aug 9.

PMID:
23928938
33.

mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.

Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, Tao J, Campos AB, Rodon J, Ibrahim YH, Serra V, Rodrik-Outmezguine V, Hazra S, Singh S, Kim P, Quadt C, Liu M, Huang A, Rosen N, Engelman JA, Scaltriti M, Baselga J.

Sci Transl Med. 2013 Jul 31;5(196):196ra99. doi: 10.1126/scitranslmed.3005747.

34.

Alternating hexagonal and striped patterns in Faraday surface waves.

Périnet N, Juric D, Tuckerman LS.

Phys Rev Lett. 2012 Oct 19;109(16):164501. Epub 2012 Oct 19.

PMID:
23215083
35.

Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment.

Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, Li Y, Wirth LJ, Dias-Santagata D.

Clin Cancer Res. 2013 Jan 15;19(2):480-90. doi: 10.1158/1078-0432.CCR-12-1842. Epub 2012 Nov 27.

36.

Prevalence, treatment and control of hypertension in a Croatian endemic nephropathy area.

Dika Ž, Juras J, Kos J, Edwards K, Fištrek M, Premužić V, Laganović M, Abramović-Baríc M, Cvitković A, Vuković Lela I, Karanović S, Jurić D, Bitunjac M, Teskera T, Jelaković B.

Kidney Blood Press Res. 2012;35(6):678-86. doi: 10.1159/000338956. Epub 2012 Oct 30.

37.

Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors.

Juric D, Baselga J.

J Clin Oncol. 2012 Mar 10;30(8):765-6. doi: 10.1200/JCO.2011.39.6390. Epub 2012 Jan 23. No abstract available.

PMID:
22271482
38.

Could disappearance of endemic (Balkan) nephropathy be expected in forthcoming decades?

Cvitković A, Vuković-Lela I, Edwards KL, Karanović S, Jurić D, Cvorišćec D, Fuček M, Jelaković B.

Kidney Blood Press Res. 2012;35(3):147-52. doi: 10.1159/000333836. Epub 2011 Nov 23.

39.

Simultaneous chickenpox and measles infection among migrant children who stayed in Italy during the second half of June 2011.

Ivić-Hofman I, Cvitković A, Kaić B, Vilibić-Čavlek T, Pandak N, Marić Z, Jurić D.

Clin Pract. 2011 Nov 10;1(4):e113. doi: 10.4081/cp.2011.e113. eCollection 2011 Sep 28.

40.

Involvement of histaminergic receptor mechanisms in the stimulation of NT-3 synthesis in astrocytes.

Jurič DM, Mele T, Carman-Kržan M.

Neuropharmacology. 2011 Jun;60(7-8):1309-17. doi: 10.1016/j.neuropharm.2011.01.019. Epub 2011 Jan 27.

PMID:
21276809
41.

Cervix cancer screening in Croatia within the European Cervical Cancer Prevention Week.

Skopljanac-Macina L, Mahovlić V, Ovanin-Rakić A, Barisić A, Rajhvajn S, Juric D, Babić D, Corusić A, Oresković S.

Coll Antropol. 2010 Jun;34(2):613-7.

PMID:
20698138
42.

Cytology of cervical intraepithelial glandular lesions.

Ovanin-Rakić A, Mahovlić V, Audy-Jurković S, Barisić A, Skopljanac-Macina L, Jurić D, Rajhvajn S, Ilić-Forko J, Babić D, Folnović D, Kani D.

Coll Antropol. 2010 Jun;34(2):401-6.

PMID:
20698109
43.

Defects in ryanodine receptor function are associated with systolic dysfunction in rats subjected to volume overload.

Juric D, Yao X, Thandapilly S, Louis X, Cantor E, Chaze B, Wojciechowski P, Vasanji Z, Yang T, Wigle J, Netticadan T.

Exp Physiol. 2010 Aug;95(8):869-79. doi: 10.1113/expphysiol.2009.052100. Epub 2010 May 14.

44.

Digital morphometry of cytologic aspirate endometrial samples.

Mahovlić V, Ovanin-Rakić A, Skopljanac-Macina L, Barisić A, Rajhvajn S, Juric D, Projić IS, Ilić-Forko J, Babić D, Skrablin-Kucić S, Bozikov J.

Coll Antropol. 2010 Mar;34(1):45-51.

PMID:
20437635
45.

Cytologic characteristics of adenoid cystic carcinoma of the cervix uteri--case report.

Barisić A, Mahovlić V, Ovanin-Rakić A, Skopljanac-Macina L, Rajhvajn S, Juric D, Babić D.

Coll Antropol. 2010 Mar;34(1):233-5.

PMID:
20432755
46.

Liquid-based cytology--new possibilities in the diagnosis of cervical lesions.

Juric D, Mahovlić V, Rajhvajn S, Ovanin-Rakić A, Skopljanac-Macina L, Barisić A, Projić IS, Babić D, Susa M, Corusić A, Oresković S.

Coll Antropol. 2010 Mar;34(1):19-24.

PMID:
20432728
47.

Resveratrol arrests and regresses the development of pressure overload- but not volume overload-induced cardiac hypertrophy in rats.

Wojciechowski P, Juric D, Louis XL, Thandapilly SJ, Yu L, Taylor C, Netticadan T.

J Nutr. 2010 May;140(5):962-8. doi: 10.3945/jn.109.115006. Epub 2010 Mar 24.

PMID:
20335634
48.

Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure.

Thandapilly SJ, Wojciechowski P, Behbahani J, Louis XL, Yu L, Juric D, Kopilas MA, Anderson HD, Netticadan T.

Am J Hypertens. 2010 Feb;23(2):192-6. doi: 10.1038/ajh.2009.228. Epub 2009 Nov 26.

PMID:
19942861
49.

Regulatory role of monoamine neurotransmitters in astrocytic NT-3 synthesis.

Mele T, Carman-Krzan M, Juric DM.

Int J Dev Neurosci. 2010 Feb;28(1):13-9. doi: 10.1016/j.ijdevneu.2009.10.003. Epub 2009 Oct 23.

PMID:
19854260
50.

Noradrenergic stimulation of BDNF synthesis in astrocytes: mediation via alpha1- and beta1/beta2-adrenergic receptors.

Juric DM, Loncar D, Carman-Krzan M.

Neurochem Int. 2008 Jan;52(1-2):297-306. Epub 2007 Jul 4.

PMID:
17681645

Supplemental Content

Support Center